Kyverna Therapeutics, Inc. KYTX Proceeds from issuance of preferred stock
Proceeds from issuance of preferred stock at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed November 13, 2024, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s proceeds from issuance of preferred stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s proceeds from issuance of preferred stock?
- Kyverna Therapeutics, Inc. (KYTX) reported proceeds from issuance of preferred stock of $34.84M in Q3 2023.
- What does proceeds from issuance of preferred stock mean?
- Cash received from issuing preferred stock — hybrid equity that provides fixed dividends without common stock dilution.